Compounds, salts thereof and methods for treatment of diseases
Inventors
Burstein, Ethan S. • Olsson, Roger • BORGSTRÖM, Björn Gustav • JANSSON, Karl Erik • SKÖLD, Niklas Patrik • Von Wachenfeldt, Henrik • WAHLSTRÖM, Larisa Yudina
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12139477-B2
Publication Date
2024-11-12
Expiration Date
Abstract
The present disclosure relates to compounds according to Formula (I), useful for treating diseases.
Core Innovation
The disclosure relates to methods for treating disease in a patient by administering an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or deuterated analogue thereof. The compounds are defined by structural parameters including m and n being 1, p and q being independently an integer selected from 0, 1, 2, 3, and 4, X being O, and fluoro substitution at R1 and R1d with R1a, R1b, and Rc as hydrogen.
The Formula (I) scope further defines R2, R2a, R2b, R2c, and R2d with allowed substituent groups and ring-system-forming combinations, together with specified selections for R3, R4a, R4b, R5a, R5b, R6, R7, and R8. In narrower recitations, R2 is limited to named alkoxy, fluoroalkoxy, hydroxyalkoxy, difluoroalkoxy, and related ether options, or the disclosure selects from enumerated specific urea compounds.
The disease-treatment scope is selected from post-traumatic stress disorder (PTSD), autism, general anxiety disorder, panic attacks, psychosis, Alzheimer's disease dementia, Lewy body dementia, Parkinson's disease dementia, Parkinson's disease depression, vascular dementia, frontotemporal dementia, negative symptoms of schizophrenia, mild cognitive impairment (MCI), insomnia, major depression, and treatment-resistant depression. Some dependent claim coverage further narrows psychosis to Alzheimer's disease psychosis or Parkinson's disease psychosis.
Claims Coverage
The consolidated claims coverage includes three independent method claims directed to treating disease by administering an effective amount of a Formula (I) compound, or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or deuterated analogue. The claims collectively emphasize the structural framework with X = O, m and n = 1, fluoro at R1 and R1d, hydrogen at R1a, R1b, and Rc, and additional substituent definitions or selections for R2 and related groups.
Formula (I) disease treatment with X is O
A method for treating a disease in a patient comprising administering to the patient an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or deuterated analogue thereof, wherein m and n are 1; p and q are independently an integer selected from 0, 1, 2, 3, and 4; R1 and R1d are fluoro; R1a, R1b, and Rc are hydrogen; and X is O, with the disease selected from the enumerated psychiatric and neurodegenerative conditions.
Restricted R2 alkoxy and ether options
A method for treating a disease in a patient comprising administering to the patient an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or deuterated analogue thereof, wherein R2 is selected from a specified group of alkoxy, fluoroalkoxy, hydroxyalkoxy, difluoroalkoxy, and related ether substituents, with X is O and the same disease selection list.
Selected named urea compounds
A method for treating a disease in a patient comprising administering to the patient an effective amount of a compound, or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or deuterated analogue thereof, selected from a group consisting of specifically named urea compounds, with the disease selected from the same enumerated group.
The claims cover disease-treatment methods using Formula (I) urea-like compounds with fixed fluoro and hydrogen constraints, X = O, and either broad substituent definitions, a narrowed R2 option set, or an enumerated list of specific urea compounds. The claimed diseases are limited to the stated psychiatric, cognitive, dementia, and depression-related conditions.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Treating a disease in a patient by administering an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or deuterated analogue, where the disease is selected from the enumerated psychiatric and neurodegenerative conditions.
Treating psychosis in a patient, where the psychosis is selected from Alzheimer's disease psychosis or Parkinson's disease psychosis.
Interested in licensing this patent?